• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Zentek Provides Market Update on ZenGUARD(TM) Antimicrobial Surgical Masks

    10/17/24 8:00:00 AM ET
    $HSIC
    $ZTEK
    Medical Specialities
    Health Care
    Major Chemicals
    Industrials
    Get the next $HSIC alert in real time by email

    GUELPH, ON / ACCESSWIRE / October 17, 2024 / Zentek Ltd. ("Zentek" or the "Company") (NASDAQ:ZTEK)(TSXV:ZEN), an intellectual property development and commercialization company, is pleased to provide an update on recent commercialization activities for its ZenGUARD™Antimicrobial Surgical Masks.

    As previously announced on July 24, 2024, the Company embarked on a Canada-wide sampling program for dental professionals facilitated by Henry Schein Inc. ("Henry Schein") that saw ZenGUARD™ Antimicrobial Surgical Masks included in product shipments to Henry Schein customers across Canada. As a result of this program and the unique value proposition ZenGUARD™ Antimicrobial Surgical Masks bring to dental practitioners and their patients, the Company is now seeing increased demand from Henry Schein. Henry Schein (NASDAQ:HSIC) is the world's largest provider of health care solutions to office-based dental and medical practitioners with a presence in 33 countries.

    Zentek continues to explore opportunities in other markets including in the beauty space and in international healthcare and dental markets where demand for surgical masks is expected to be more stable long term.

    As previously announced on April 24, 2024, the Company applied to the Food and Drug Administration (FDA) for authorization to market and sell its ZenGUARD™ Surgical Masks in the United States. The FDA has requested additional information regarding ZenGUARD™ and the Company is currently evaluating the additional information requests.

    "In addition to better protection against infectious agents, ZenGUARD™ Antimicrobial Surgical Masks are also proven to eliminate 99.9% of bacteria, which can collect on the skin when wearing a surgical mask for extended periods and cause acne. We believe this unique value proposition will continue to drive increased demand in the dental market and is a very natural fit for the beauty industry as well. We look forward to continuing to build on the recent success generated in the Henry Schein sampling program and to expanding the platform globally." said Greg Fenton, Zentek CEO.

    About Zentek Ltd.

    Zentek is an ISO 13485:2016 certified intellectual property technology company focused on the research, development and commercialization of novel products seeking to give the Company's commercial partners a competitive advantage by making their products better, safer, and greener.

    Zentek's patented technology platform ZenGUARD™, is shown to have 99-per-cent antimicrobial activity and to significantly increase the viral filtration efficiency for surgical masks and aims to do the same for HVAC (heating, ventilation, and air conditioning) systems. Zentek's ZenGUARD™ production facility is in Guelph, Ontario.

    For further information on Zentek:

    [email protected]

    Ryan Shacklock
    Senior VP, Strategy & Business Development
    Email: [email protected]
    Phone: 306-270-9610

    To find out more about Zentek, please visit our website at www.Zentek.com. A copy of this news release and all material documents in respect of the Company may be obtained on Zentek's SEDAR+ profile at http://www.sedarplus.ca/.

    Forward-Looking Statements

    This news release contains forward-looking statements. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although Zentek believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Zentek disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

    Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

    SOURCE: Zentek Ltd.



    View the original press release on accesswire.com

    Get the next $HSIC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Q&A

    New
    • What recent developments have been reported regarding Zentek's ZenGUARD™ Surgical Masks?

      Zentek Ltd. has reported an increase in demand for their ZenGUARD™ Antimicrobial Surgical Masks, particularly through a sampling program for dental professionals facilitated by Henry Schein Inc.

    • In addition to the dental market, what other markets is Zentek exploring for their surgical masks?

      Zentek is exploring opportunities in various markets, especially the beauty space and international healthcare and dental markets that show stable long-term demand for surgical masks.

    • What is the current status of Zentek's FDA application for ZenGUARD™ Surgical Masks?

      The FDA has requested additional information from Zentek regarding their application to market and sell ZenGUARD™ Surgical Masks in the United States, which is currently being evaluated by the Company.

    • What unique benefits do ZenGUARD™ Surgical Masks offer beyond protection from infectious agents?

      ZenGUARD™ Antimicrobial Surgical Masks are claimed to eliminate 99.9% of bacteria that can cause acne, making them not just protective but also beneficial for the skin.

    • What are Zentek's expectations for the future following the success of their recent sampling program?

      The Company is optimistic about its growth and global expansion plans, especially following the success from the Henry Schein sampling program.

    Recent Analyst Ratings for
    $HSIC
    $ZTEK

    CompanyDatePrice TargetRatingAnalyst
    Henry Schein Inc.
    $HSIC
    8/26/2025$83.00In-line → Outperform
    Evercore ISI
    Henry Schein Inc.
    $HSIC
    7/25/2025$75.00Buy → Hold
    Stifel
    Henry Schein Inc.
    $HSIC
    7/14/2025$72.00Outperform → Neutral
    Robert W. Baird
    Henry Schein Inc.
    $HSIC
    2/14/2025$80.00Equal Weight
    Wells Fargo
    Henry Schein Inc.
    $HSIC
    1/6/2025$69.00 → $84.00Underperform → Buy
    BofA Securities
    Henry Schein Inc.
    $HSIC
    12/4/2024$75.00Neutral
    Mizuho
    Henry Schein Inc.
    $HSIC
    7/22/2024$81.00 → $92.00Neutral → Outperform
    Robert W. Baird
    Henry Schein Inc.
    $HSIC
    2/26/2024$78.00Market Perform
    Leerink Partners
    More analyst ratings

    $HSIC
    $ZTEK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Daniel William K bought $670,800 worth of shares (10,000 units at $67.08) (SEC Form 4)

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    8/11/25 4:26:33 PM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    $ZTEK
    SEC Filings

    View All

    SEC Form 8-K filed by Henry Schein Inc.

    8-K - HENRY SCHEIN INC (0001000228) (Filer)

    9/9/25 4:05:20 PM ET
    $HSIC
    Medical Specialities
    Health Care

    SEC Form 6-K filed by Zentek Ltd.

    6-K - Zentek Ltd. (0001904501) (Filer)

    9/4/25 9:42:13 AM ET
    $ZTEK
    Major Chemicals
    Industrials

    SEC Form 6-K filed by Zentek Ltd.

    6-K - Zentek Ltd. (0001904501) (Filer)

    9/3/25 10:07:16 AM ET
    $ZTEK
    Major Chemicals
    Industrials

    $HSIC
    $ZTEK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Henry Schein Announces $750 Million Share Repurchase Plan

    Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care products and services to office-based dental and medical practitioners, announced today that its Board of Directors has authorized the repurchase of up to $750 million of shares of the Company's common stock. This program is in addition to the $500 million repurchase program announced in January 2025, which is anticipated to be fully executed by the end of the first quarter of 2026. The Company had approximately 118.6 million shares outstanding as of September 8, 2025. This new authorization represents approximately 9.0 percent of shares outstanding at the current stock price. Purchases may be made from time t

    9/9/25 5:10:00 PM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Medical Expands SolutionsHub with Colaborate

    Full-Service Laboratory Management Firm Helps Elevate Clinical Lab Operations NEW YORK, Sept. 9, 2025 /PRNewswire/ -- Henry Schein Medical, the U.S. medical business of Henry Schein, Inc., has expanded its SolutionsHub™ with the addition of Colaborate, a full-service management consulting firm dedicated to serving independent and hospital-based medical laboratories. Together, Henry Schein and Colaborate will empower clinical laboratories across the U.S. to maintain compliance, enhance operational efficiency, and increase financial sustainability. Through this expansion, labora

    9/9/25 10:18:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein to Participate in Upcoming Investor Conferences in September

    Henry Schein, Inc., the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that the Company will present at the following investor conferences in September: Wells Fargo Healthcare Conference at the Encore Boston hotel, Boston, MA, on September 4, 2025, at 11:00 a.m. EST. Baird Global Healthcare Conference at the InterContinental hotel, New York City, on September 10, 2025, at 10:50 a.m. EST. Bank of America Global Healthcare Conference at Bank of America Headquarters, London, UK, on September 24, 2025, at 9:50 a.m. BST/4:50 a.m. EST. Henry Schein's presentations can be heard via live webcast by visiting www.henrysc

    8/22/25 6:30:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    $ZTEK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Henry Schein upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded Henry Schein from In-line to Outperform and set a new price target of $83.00

    8/26/25 8:13:41 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein downgraded by Stifel with a new price target

    Stifel downgraded Henry Schein from Buy to Hold and set a new price target of $75.00

    7/25/25 8:58:32 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded Henry Schein from Outperform to Neutral and set a new price target of $72.00

    7/14/25 8:40:13 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    $ZTEK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman, CEO Bergman Stanley M gifted 550 units of Common Stock par value $0.01 per shre, decreasing direct ownership by 0.17% to 321,547 units (SEC Form 4)

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    9/11/25 4:50:34 PM ET
    $HSIC
    Medical Specialities
    Health Care

    New insider Kkr Hawaii Holdings L.P. claimed ownership of 15,263,662 shares (SEC Form 3)

    3 - HENRY SCHEIN INC (0001000228) (Issuer)

    8/15/25 9:30:38 PM ET
    $HSIC
    Medical Specialities
    Health Care

    SEC Form 4 filed by Large owner Kkr Hawaii Aggregator L.P.

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    8/14/25 7:00:45 PM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    $ZTEK
    Leadership Updates

    Live Leadership Updates

    View All

    Stanley M. Bergman to Retire as Henry Schein's Chief Executive Officer at the End of 2025

    Mr. Bergman to Continue to Serve as Chairman of the Board Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that Stanley M. Bergman will retire as Chief Executive Officer (CEO) at the end of the year after 45 years at the Company, including more than 35 years as CEO. Mr. Bergman will continue to lead Henry Schein in his current role until his retirement and will remain as Chairman thereafter. The Board is commencing a formal search process in conjunction with a nationally recognized executive search firm and will consider internal and external candidates. "With the progress made advan

    7/15/25 7:05:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Announces Completion of Strategic Investment by KKR and Appointment of Dan Daniel to Board of Directors

    Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today announced the successful completion of a $250 million strategic investment by funds affiliated with KKR, a leading global investment firm. Upon the closing of this transaction, KKR has become the holder of approximately 12% of the common shares of Henry Schein. In connection with the investment, William K. "Dan" Daniel, Executive Advisor to KKR and former Executive Vice President of Danaher Corporation, has officially joined Henry Schein's Board of Directors as an independent director. He joins Max Lin, Partner at KKR and leader of the firm's Healt

    5/16/25 4:10:00 PM ET
    $HSIC
    $KKR
    Medical Specialities
    Health Care
    Investment Managers
    Finance

    PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

    Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca

    3/11/25 7:05:00 AM ET
    $BAX
    $BMRN
    $EMBC
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Medical Specialities

    $HSIC
    $ZTEK
    Financials

    Live finance-specific insights

    View All

    Henry Schein Reports Second Quarter 2025 Financial Results

    Second-quarter 2025 GAAP diluted EPS of $0.70, compared to $0.80 GAAP diluted EPS in the second quarter of 2024 Second-quarter 2025 non-GAAP diluted EPS of $1.10, compared to $1.23 non-GAAP diluted EPS in the second quarter of 2024 Maintains guidance for 2025 non-GAAP diluted EPS of $4.80 to $4.94, mid-single digit 2025 Adjusted EBITDA growth, and sales growth of 2% to 4% Takes next steps in collaboration with KKR to pursue additional opportunities to create shareholder value Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the second quarter ended June

    8/5/25 6:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein to Webcast Second Quarter 2025 Conference Call on Tuesday, August 5, 2025, at 8:00 a.m. ET

    Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that it will release its second quarter 2025 financial results before the stock market opens on Tuesday, August 5, 2025, and will provide a live webcast of its earnings conference call on the same day beginning at 8:00 a.m. Eastern time. Speakers on the call will include Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein, and Ronald N. South, Senior Vice President and Chief Financial Officer. Investors can access the call by visiting https://investor.henryschein.com/webcasts. A replay will be available

    7/22/25 6:30:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Reports First Quarter 2025 Financial Results

    First-quarter 2025 GAAP diluted EPS of $0.88, growth of 22% compared to the first quarter of 2024 First-quarter 2025 non-GAAP diluted EPS of $1.15, growth of 4.5% compared to the first quarter of 2024 Maintains guidance for 2025 non-GAAP diluted EPS of $4.80 to $4.94, mid-single digit 2025 Adjusted EBITDA growth, and sales growth of 2% to 4% Repurchased $161 million of common stock, or approximately 2.3 million shares Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the first quarter ended March 29, 2025. "We are pleased with our first quarter financial re

    5/5/25 6:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    $ZTEK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Henry Schein Inc.

    SC 13G/A - HENRY SCHEIN INC (0001000228) (Subject)

    11/13/24 3:30:01 PM ET
    $HSIC
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Henry Schein Inc.

    SC 13G - HENRY SCHEIN INC (0001000228) (Subject)

    11/12/24 9:32:27 AM ET
    $HSIC
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Henry Schein Inc. (Amendment)

    SC 13G/A - HENRY SCHEIN INC (0001000228) (Subject)

    2/14/24 11:18:57 AM ET
    $HSIC
    Medical Specialities
    Health Care